Myelodysplastic Syndromes (MDS)

NMDP and CIBMTR share new, promising stem cell transplantation trial data using mismatched, unrelated donors at the 2024 EHA Congress

Original Publication Date

June 14, 2024

Article Source

External Web Content

MINNEAPOLIS, June 14, 2024 — NMDPSM, a global nonprofit leader in cell therapy, and the CIBMTR® (Center for International Blood and Marrow Transplant Research®) announced interim results from the ACCESS trial as an oral abstract during the European Hematology Association (EHA)…

Alain MIna, MD

Institution

National Cancer Institute - NCI

Physician Status

accepting new patients

Primary Disease Area of Focus

Acute Myeloid Leukemia (AML)

Myelodysplastic Syndromes (MDS)

Read more about Alain MIna, MD

FDA approves imetelstat for low- to intermediate-1 risk myelodysplastic syndromes with transfusion-dependent anemia

Original Publication Date

June 6, 2024

Article Source

External Web Content

On June 6, 2024, the Food and Drug Administration approved imetelstat (Rytelo, Geron Corporation), an oligonucleotide telomerase inhibitor, for adults with low- to intermediate-1 risk myelodysplastic syndromes (MDS) with transfusion-dependent anemia requiring four or more red…

Blood Transfusions and Iron Overload

Thumbnail for video Watch Now

Topic(s)

Living Well with Bone Marrow Failure

Managing Your Treatment

In this webinar, Dr. Thomas Coates will discuss blood transfusions and the potential side effect, iron overload. You may submit questions in advance by emailing help@aamds.org.

Toward a more patient-centered drug development process in clinical trials for patients with myelodysplastic syndromes/neoplasms (MDS): Practical considerations from the International Consortium for MDS (icMDS)

Read more about Toward a more patient-centered drug development process in clinical trials for patients with myelodysplastic syndromes/neoplasms (MDS): Practical considerations from the International Consortium for MDS (icMDS)

Notable treatment advances have been made in recent years for patients with myelodysplastic syndromes myelodysplastic syndromes:

Clinical and Genomic-Based Decision Support System to Define the Optimal Timing of Allogeneic Hematopoietic Stem-Cell Transplantation in Patients With Myelodysplastic Syndromes

Read more about Clinical and Genomic-Based Decision Support System to Define the Optimal Timing of Allogeneic Hematopoietic Stem-Cell Transplantation in Patients With Myelodysplastic Syndromes

Purpose: Allogeneic hematopoietic stem-cell transplantation (HSCT) is the only potentially curative treatment for patients with myelodysplastic syndromes

Advances in the management of higher-risk myelodysplastic syndromes: future prospects

Read more about Advances in the management of higher-risk myelodysplastic syndromes: future prospects

Higher-risk myelodysplastic syndromes myelodysplastic syndromes: (my-eh-lo-diss-PLASS-tik SIN-dromez) A group of disorders wh

Understanding Secondary AML: High-Risk MDS to AML

Thumbnail for video Watch Now

Topic(s)

Myelodysplastic Syndromes (MDS)

Acute Myeloid Leukemia (AML)

Presenter(s)

Nathan Punwani, MD, MPH

In this webinar, Dr. Nathan Punwani discusses the development of secondary AML from high risk MDS, treatment options and the quality of life impact for patients.

Early transfusion patterns improve the Molecular International Prognostic Scoring System (IPSS-M) prediction in myelodysplastic syndromes

Read more about Early transfusion patterns improve the Molecular International Prognostic Scoring System (IPSS-M) prediction in myelodysplastic syndromes

Background: The Molecular International Prognostic Scoring System

Treatment of Myelodysplastic Syndromes for Older Patients: Current State of Science, Challenges, and Opportunities

Read more about Treatment of Myelodysplastic Syndromes for Older Patients: Current State of Science, Challenges, and Opportunities

Purpose of review: Myelodysplastic syndromes Myelodysplastic syndromes: (my-eh-lo-diss-PLASS-tik SIN-dr

Subscribe to Myelodysplastic Syndromes (MDS)

Your Gift Today Changes Lives

Myelodysplastic Syndromes (MDS)

NMDP and CIBMTR share new, promising stem cell transplantation trial data using mismatched, unrelated donors at the 2024 EHA Congress

Alain MIna, MD

FDA approves imetelstat for low- to intermediate-1 risk myelodysplastic syndromes with transfusion-dependent anemia

Blood Transfusions and Iron Overload

Toward a more patient-centered drug development process in clinical trials for patients with myelodysplastic syndromes/neoplasms (MDS): Practical considerations from the International Consortium for MDS (icMDS)

Clinical and Genomic-Based Decision Support System to Define the Optimal Timing of Allogeneic Hematopoietic Stem-Cell Transplantation in Patients With Myelodysplastic Syndromes

Advances in the management of higher-risk myelodysplastic syndromes: future prospects

Understanding Secondary AML: High-Risk MDS to AML

Early transfusion patterns improve the Molecular International Prognostic Scoring System (IPSS-M) prediction in myelodysplastic syndromes

Treatment of Myelodysplastic Syndromes for Older Patients: Current State of Science, Challenges, and Opportunities

Website Feedback

Patient Helpline